504
Views
28
CrossRef citations to date
0
Altmetric
Drug Evaluation

Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease

, MD, , MD, , MD MSc, , PhD & , PhD
Pages 1489-1506 | Published online: 22 Aug 2007

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Ana Martinez & Carmen Gil. (2014) cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opinion on Therapeutic Patents 24:12, pages 1311-1321.
Read now
Stephen J Bickston, Kenneth R Snider & Matthew R Kappus. (2012) Tetomilast: new promise for phosphodiesterase-4 inhibitors?. Expert Opinion on Investigational Drugs 21:12, pages 1845-1849.
Read now
Pooneh Salari & Mohammad Abdollahi. (2012) Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opinion on Investigational Drugs 21:3, pages 261-264.
Read now

Articles from other publishers (25)

Feng Zhou, Nan-Zhen Wu, Yong Xie & Xiao-Jiang Zhou. (2023) Intestinal barrier in inflammatory bowel disease: A bibliometric and knowledge-map analysis. World Journal of Gastroenterology 29:36, pages 5254-5267.
Crossref
Naif O. Al-Harbi, Faisal Imam, Mohammad Matar Al-Harbi, Khaldoon Aljeryan, Othman A. Al-Shabanah, Khaled A. Alhosaini, Lamya Saif Alqahtani, Muhammad Afzal, M.D. Khalid Anwer, Abdullah A. Aldossari, Mohammed M. Alanazi, Sary Alsanea & Mohammed A. Assiri. (2022) Protective effect of Apremilast against LPS-induced acute lung injury via modulation of oxidative stress and inflammation. Saudi Journal of Biological Sciences 29:5, pages 3414-3424.
Crossref
Irene Marafini, Edoardo Troncone, Silvia Salvatori & Giovanni Monteleone. (2020) TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases. Pharmacological Research 155, pages 104757.
Crossref
Peter H. Schafer, Mary Adams, Gerald Horan, Francesca Truzzi, Alessandra Marconi & Carlo Pincelli. (2019) Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice. Drugs in R&D 19:4, pages 329-338.
Crossref
Marco Spadaccini, Silvia D’Alessio, Laurent Peyrin-Biroulet & Silvio Danese. (2017) PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. International Journal of Molecular Sciences 18:6, pages 1276.
Crossref
Naiem T. Issa, Jordan Kruger, Henri Wathieu, Rajarajan Raja, Stephen W. Byers & Sivanesan Dakshanamurthy. (2016) DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing. BMC Bioinformatics 17:1.
Crossref
Peter H. Schafer, Francesca Truzzi, Anastasia Parton, Lei Wu, Jolanta Kosek, Ling-Hua Zhang, Gerald Horan, Annalisa Saltari, Marika Quadri, Roberta Lotti, Alessandra Marconi & Carlo Pincelli. (2016) Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cellular Signalling 28:7, pages 753-763.
Crossref
So Motoyoshi, Yasuhiko Yamamoto, Seiichi Munesue, Hirobumi Igawa, Ai Harashima, Hidehito Saito, Dong Han, Takuo Watanabe, Hiroshi Sato & Hiroshi Yamamoto. (2014) cAMP ameliorates inflammation by modulation of macrophage receptor for advanced glycation end-products. Biochemical Journal 463:1, pages 75-82.
Crossref
Monalisa F. AzevedoFabio R. FauczEirini BimpakiAnelia HorvathIsaac LevyRodrigo B. de AlexandreFaiyaz AhmadVincent ManganielloConstantine A. Stratakis. (2014) Clinical and Molecular Genetics of the Phosphodiesterases (PDEs). Endocrine Reviews 35:2, pages 195-233.
Crossref
Huey-Yi Chen, Wen-Chi Chen, Yu-Ning Lin & Yung-Hsiang Chen. (2014) Synergistic Effect of Vaginal Trauma and Ovariectomy in a Murine Model of Stress Urinary Incontinence: Upregulation of Urethral Nitric Oxide Synthases and Estrogen Receptors. Mediators of Inflammation 2014, pages 1-8.
Crossref
Pascal Juillerat & Joshua R. Korzenik. 2014. Medical Therapy of Ulcerative Colitis. Medical Therapy of Ulcerative Colitis 221 235 .
Neal Kumar, Ari M Goldminz, Noori Kim & Alice B Gottlieb. (2013) Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Medicine 11:1.
Crossref
Peter Schafer. (2012) Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochemical Pharmacology 83:12, pages 1583-1590.
Crossref
Dalip Kumar, Gautam Patel, Lalitha Vijayakrishnan, Sunanda G. Dastidar & Abhijit Ray. (2012) Design and Synthesis of 3,5-Disubstituted-1,2,4-Oxadiazoles as Potent Inhibitors of Phosphodiesterase4B2. Chemical Biology & Drug Design 79:5, pages 810-818.
Crossref
Klaus F. Rabe. (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. British Journal of Pharmacology 163:1, pages 53-67.
Crossref
Hermann Tenor, Armin Hatzelmann, Rolf Beume, Gezim Lahu, Karl Zech & Thomas D. Bethke. 2011. Phosphodiesterases as Drug Targets. Phosphodiesterases as Drug Targets 85 119 .
C. P. Page & D. Spina. 2011. Phosphodiesterases as Drug Targets. Phosphodiesterases as Drug Targets 391 414 .
Mohammad Ali Rezvanfar, Mohammad Amin Rezvanfar, Akram Ranjbar, Maryam Baeeri, Azadeh Mohammadirad & Mohammad Abdollahi. (2010) Biochemical evidence on positive effects of rolipram a phosphodiesterase-4 inhibitor in malathion-induced toxic stress in rat blood and brain mitochondria. Pesticide Biochemistry and Physiology 98:1, pages 135-143.
Crossref
Jieru E. Lin, Michael Valentino, Glen Marszalowicz, Michael S. Magee, Peng Li, Adam E. Snook, Brian A. Stoecker, Chang Chang & Scott A. Waldman. (2010) Bacterial Heat-Stable Enterotoxins: Translation of Pathogenic Peptides into Novel Targeted Diagnostics and Therapeutics. Toxins 2:8, pages 2028-2054.
Crossref
Miles Houslay & Marco Conti. (2010) Phosphodiesterase 4D, cAMP specific. AfCS-Nature Molecule Pages.
Crossref
PH Schafer, A Parton, AK Gandhi, L Capone, M Adams, L Wu, JB Bartlett, MA Loveland, A Gilhar, Y-F Cheung, GS Baillie, MD Houslay, H-W Man, GW Muller & DI Stirling. (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. British Journal of Pharmacology 159:4, pages 842-855.
Crossref
Sevgin Ozlem Iseri, Yasemin Ersoy, Feriha Ercan, Meral Yuksel, Pinar Atukeren, Koray Gumustas & Inci Alican. (2009) The effect of sildenafil, a phosphodiesterase-5 inhibitor, on acetic acid-induced colonic inflammation in the rat. Journal of Gastroenterology and Hepatology 24:6, pages 1142-1148.
Crossref
John A. Meyers, Derrick W. Su & Adam Lerner. (2009) Chronic Lymphocytic Leukemia and B and T Cells Differ in Their Response to Cyclic Nucleotide Phosphodiesterase Inhibitors. The Journal of Immunology 182:9, pages 5400-5411.
Crossref
Neil J. Press & Katharine H. Banner. 2009. Progress in Medicinal Chemistry Volume 47. Progress in Medicinal Chemistry Volume 47 37 74 .
Amanda P. Skoumbourdis, Ruili Huang, Noel Southall, William Leister, Vicky Guo, Ming-Hsuang Cho, James Inglese, Marshall Nirenberg, Christopher P. Austin, Menghang Xia & Craig J. Thomas. (2008) Identification of a potent new chemotype for the selective inhibition of PDE4. Bioorganic & Medicinal Chemistry Letters 18:4, pages 1297-1303.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.